AEMD — Aethlon Medical Share Price
Last Trade - 00:00- $54.75m
- $44.75m
- $0.66m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Mar | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.39 | 0.15 | 0.23 | 0.65 | 0.66 | 1.93 | 95.2 | -5.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.
Directors
- Edward Broenniman CHM (84)
- Charles Fisher CEO (74)
- James Frakes CFO (63)
- Guy Cipriani SVP (50)
- Steven Larosa
- Sabrina Johnson (54)
- Chetan Shah (51)
- Last Annual
- March 31st, 2021
- Last Interim
- March 31st, 2021
- Incorporated
- April 17th, 1991
- Public Since
- March 9th, 1994
- No. of Shareholders
- 67
- No. of Employees
- 10
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 15,378,609
- Address
- 9635 Granite Ridge Dr Ste 100, SAN DIEGO, 92123
- Web
- https://www.aethlonmedical.com/
- Phone
- +1 8584597800
- Contact
- James Frakes
- Auditors
- BAKER TILLY US LLP
Latest News for AEMD
Upcoming events for AEMD
Aethlon Medical Inc Annual Shareholders Meeting
Q2 2022 Aethlon Medical Inc Earnings Release
Similar to AEMD
ACCELERATE DIAGNOSTICS ORD
NASDAQ Capital Market
ALLIED HEALTHCARE PRODUCTS ORD
NASDAQ Capital Market
AXOGEN ORD
NASDAQ Capital Market
BIOLASE ORD
NASDAQ Capital Market
BIONANO GENOMICS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in Aethlon Medical are trading at $3.56. This share price information is delayed by 15 minutes.
Shares in Aethlon Medical last closed at $3.56 and the price had moved by +126.75% over the past 365 days. In terms of relative price strength the Aethlon Medical share price has outperformed the S&P500 Index by +72.03% over the past year.
The overall consensus recommendation for Aethlon Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aethlon Medical does not currently pay a dividend.
Aethlon Medical does not currently pay a dividend.
Aethlon Medical does not currently pay a dividend.
To buy shares in Aethlon Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.56, shares in Aethlon Medical had a market capitalisation of $54.75m.
Here are the trading details for Aethlon Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AEMD
Based on an overall assessment of its quality, value and momentum Aethlon Medical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Aethlon Medical is $9.33. That is 162.08% above the last closing price of $3.56.
Analysts covering Aethlon Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.51 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aethlon Medical. Over the past six months, its share price has outperformed the S&P500 Index by +19.26%.
As of the last closing price of $3.56, shares in Aethlon Medical were trading +28.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aethlon Medical.
Aethlon Medical's management team is headed by:
- Edward Broenniman - CHM
- Charles Fisher - CEO
- James Frakes - CFO
- Guy Cipriani - SVP
- Steven Larosa -
- Sabrina Johnson -
- Chetan Shah -
We do not have data on Aethlon Medical's shareholders